Rosemarie Kientsch-Engel

This inventor holds 8 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Boehringer Mannheim Gmbh, Roche Diagnostics Operations, Inc., Roche Diagnostics Gmbh. Active years: 1990-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rosemarie Kientsch-Engel. Retrieved from https://idiyas.com/inventor/rosemarie-kientsch-engel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 75.0

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 55(Granted Patents)

Location History:

Pahl, DE (1990)
Feldafing, DE (1999 - 2022)

Company Filing History:

3 out of 1,164

Boehringer Mannheim Gmbh

patents

3 out of 1,700

Roche Diagnostics Operations, Inc.

patents

2 out of 488

Roche Diagnostics Gmbh

patents

Years Active: 1990-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11397187 - IGFBP7 for prediction of risk of AKI when measured prior to surgery (2022-07-26),

2. 8062857 - H-FABP as early predictor of myocardial infarction (2011-11-22),

3. 7977105 - Myoglobin as early predictor of myocardial infarction (2011-07-12),

4. 6630350 - Monoclonal antibodies against a human act and serine protease complex (2003-10-07),

5. 6214568 - Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof (2001-04-10),

6. 5888813 - Monoclonal antibodies against human pancreatic islet cells (1999-03-30),

7. 5863740 - Interference eliminating agent for application in immunoassays (1999-01-26),

8. 4929543 - Process for the determination of an antibody in human body fluids (1990-05-29),

Title: Rosemarie Kientsch-Engel: Innovator in Medical Diagnostics

Introduction

Rosemarie Kientsch-Engel is a prominent inventor based in Feldafing, Germany. She has made significant contributions to the field of medical diagnostics, holding a total of 8 patents. Her work focuses on innovative methods for predicting and diagnosing critical health conditions.

Latest Patents

One of her latest patents involves the use of IGFBP7 for predicting the risk of acute kidney injury (AKI) when measured prior to surgery. This method is based on determining the level of the biomarker IGFBP7 in a body fluid sample obtained from the patient. Additionally, she has developed a method for predicting AKI risk based on the determination of both IGFBP7 and Cystatin C levels. Another significant patent relates to H-FABP as an early predictor of myocardial infarction. This invention provides a method for diagnosing myocardial infarction in subjects suffering from acute coronary syndrome, particularly when cardiac troponin levels are detectable but lower than the indicative level for myocardial infarction.

Career Highlights

Throughout her career, Rosemarie has worked with notable companies such as Boehringer Mannheim GmbH and Roche Diagnostics Operations, Inc. Her expertise in medical diagnostics has led to groundbreaking advancements in patient care and treatment protocols.

Collaborations

Rosemarie has collaborated with esteemed colleagues, including Josef Endl and Michael Brandt, contributing to the development of innovative diagnostic methods.

Conclusion

Rosemarie Kientsch-Engel's contributions to medical diagnostics through her patents and collaborations have significantly impacted the field. Her innovative approaches continue to enhance patient outcomes and advance medical technology.

Profile summary based on public USPTO records.